Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.46 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.46 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL139017 | 0.88 | CA1 (0.53) | CA12CA1CA2CA9 | |
| SCHEMBL1968355 | 0.83 | CA12 (0.66) | CA12CA1CA2CA9GAA | |
| SCHEMBL9633827 | 0.81 | MTNR1A (0.49) | ALKCA12CA1CA2CA9 | |
| SCHEMBL7273625 | 0.81 | INSR (0.50) | INSRALKCA12CA1CA2 | |
| SCHEMBL4703676 | 0.81 | INSR (0.42) | INSRALKCA12CA1CA2 | |
| SCHEMBL5010714 | 0.81 | ALDH1A1 (0.55) | GAASMN1; SMN2 | |
| SCHEMBL4703678 | 0.81 | INSR (0.42) | INSRALKCA12CA1CA2 | |
| SCHEMBL9632017 | 0.81 | ADRA1D (0.46) | ALKCA12CA1CA2CA9 | |
| SCHEMBL5913864 | 0.80 | CA12 (0.51) | CA12CA1CA2CA9GAA | |
| SCHEMBL16416372 | 0.80 | CA12 (0.51) | CA12CA1CA2CA9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2408769-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | Glaxo Group Limited (GB) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106016-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | DTYMK, ITK, DCK | INSR 999/4885ALK 1800/4885CA12 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.